TNDM
Tandem Diabetes Care, Inc.
NasdaqGM Healthcare United States
16,35 $US
-1.03% today
-24.13% YTD · +9.29% 1Y
2
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
18
Hedge funds tracked
Latest available SEC 13F filings
58
/ 100
MIXED

Analysis Tandem Diabetes Care, Inc. (TNDM) — Kairos Score 58/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Key info

👔
CEO
Mr. John F. Sheridan
📍
HQ
12400 High Bluff Drive, San Diego, CA, 92130, United States
👥
Employees
2 500
💰
Market cap
1 137 611 776,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

2 transactions — 0 buys and 0 sales reported by Tandem Diabetes Care, Inc. executives.

KJ
Kyrillos Jean-Claude
EVP & Chief Operating Officer · 2026-10-15
Other
KJ
Kyrillos Jean-Claude
EVP & Chief Operating Officer · 2026-10-15
Other

🏦 Hedge Funds

18 institutional funds report a position on TNDM in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD GROUP INC
Sessa Capital IM, L.P.
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC

📰 Recent news

15 recent articles on TNDM.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Tandem Diabetes Care, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of TNDM on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 2 insider transactions over 90 days
✅ All 18 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year